BioMarin's Roctavian gene therapy shows long-term effectiveness in treating severe hemophilia A, reducing bleeding and ...

Employers increasingly shift health benefit costs to workers in 2026, while prioritizing mental health and innovative affordability strategies.

The vision research community rallies to protect the National Eye Institute from funding cuts, emphasizing its vital role in preventing blindness and advancing treatments.

A scleroderma patient in a Sylvester Comprehensive Cancer Center trial was recently successfully treated with CAR T-cell lymphoma therapy, in what researchers are calling an “immunological reset.” ...

Panelists discuss how autoantibody testing has high diagnostic accuracy with nearly 100% conversion to hyperglycemia when two or more antibodies are present, though timing of testing is crucial and ...

Replimune's RP1 treatment for advanced melanoma faces FDA rejection due to trial design issues, despite promising results ...

Humana has released details about additional, upcoming organizational improvements to encourage a faster prior authorization ...

Audere is closing gaps in HIV care and education with the help of Amy, their artificial intelligence companion designed to ...

Sarepta officials said the temporary halt in shipments was done to maintain a productive working relationship with regulators ...

The Vision Center at Children’s Hospital Los Angeles is developing a protocol for a phase 1 clinical trial for the first gene ...

This biosimilars market report focuses on rising market complexity and recent activity, including two new approvals and four ...

An expert discusses how choosing between triplet and quadruplet regimens for transplant-ineligible multiple myeloma depends on patient fitness, disease risk, and treatment tolerability. He highlights ...